Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508956 | 0.83 | PTGS2 (0.50) | FAAHPTGS2MTNR1AMTNR1BAPAF1 | |
| SCHEMBL11850160 | 0.82 | PTGS1 (0.69) | ALDH1A1LMNAPTGS2SMN1; SMN2MAPK1 | |
| SCHEMBL4444974 | 0.82 | FAAH (0.66) | FAAHALDH1A1LMNASMN1; SMN2GSK3B | |
| SCHEMBL13389325 | 0.81 | ALDH1A1 (0.50) | FAAHALDH1A1LMNAPTGS2TRPA1 | |
| Methylene Chloride SCHEMBL28307597 | 0.81 | PTGS2 (0.64) | ALDH1A1LMNAPTGS2SMN1; SMN2MAPK1 | |
| SCHEMBL10728103 | 0.81 | PTGS2 (0.48) | FAAHPTGS2TRPA1APAF1CYP2D6 | |
| SCHEMBL3410010 | 0.81 | ALDH1A1 (0.50) | FAAHALDH1A1LMNAPTGS2TRPA1 | |
| SCHEMBL4588469 | 0.79 | PTGS2 (0.47) | FAAHPTGS2MTNR1AMTNR1BAPAF1 | |
| SCHEMBL7114570 | 0.79 | PTGS2 (0.47) | FAAHPTGS2MTNR1AMTNR1BAPAF1 | |
| SCHEMBL27332943 | 0.79 | PTGS2 (0.47) | FAAHLMNAPTGS2APAF1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025231514-A1 | ANTIVIRAL FORMULATIONS | Vapour Science (AU) | 2025-11-13 | — | — | WO | disclosed |
| CN-107430129-A | Kit for measuring virus | 休伯特保健公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-107407678-A | Kit for measuring virus | 休伯特保健公司 | 2017-11-28 | — | — | CN | disclosed |
| EP-2134692-A2 | QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION | Wyeth a Corporation of the State of Delaware (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20080255192-A1 | 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008121817-A2 | QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION | WYETH (US) | 2008-10-09 | — | — | WO | disclosed |
| EP-1573000-B1 | CRYSTAL STRUCTURE OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| EP-1573000-A2 | CRYSTAL STRUCTURE OF GLUTAMATE RACEMASE (MURI) | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| US-20050037478-A1 | Crystal structure of glutamate racemase (MurI) | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | disclosed |
| WO-2004061097-A2 | CRYSTAL STRUCTURE OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | WO | disclosed |
| US-5474700-A | Cleaning composition for degrading targeted proteinaceous contaminants | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1995-12-12 | — | — | US | disclosed |
| US-5312749-A | Industrial alkaline protease from shipworm bacterium | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1994-05-17 | — | — | US | disclosed |
| EP-0502892-A4 | THE HUMAN C3B/C4B RECEPTOR (CR1) | — | 1992-11-19 | — | — | EP | disclosed |
| EP-0502892-A1 | THE HUMAN C3b/C4b RECEPTOR (CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 1992-09-16 | — | — | EP | disclosed |
| WO-1991005047-A1 | THE HUMAN C3b/C4b RECEPTOR (CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 1991-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255192-A1 | 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins | VCAM1, ICAM1, SELE | FAAH 1252/4885ALDH1A1 346/4885LMNA 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.